Role of mannose binding lectin in response to candida antigen immunotherapy of warts

Abstract

Background

Warts is the commonest cutaneous manifestation of human papillomavirus (HPV) infection. Intralesional Candida antigen immunotherapy is used for wart treatment.

Aim

To identify the role of mannose binding lectin (MBL) in susceptibility to HPV infection and to explore the relationship between MBL and response to intralesional Candida antigen immunotherapy of wart.

Patients and methods

A case-control study was enrolled with 96 participants; 48 wart cases and 48 healthy controls. MBL serum level assay baseline and after six settings of intralesional candida antigen injection was done by ELISA technique. MBL2 gene exon 1 codon 54 polymorphism was detected by using restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR).

Results

A statistically significant difference in MBL serum level between wart cases and controls was found. An association between MBL2 exon1 codon 54 polymorphism and susceptibility to HPV infection and development of warts was proved. Carriage of genotype AB was more frequent wart cases (95.8%) than in controls (20.8%). No statistical significance association could be found between the therapeutic response to Candida antigen immunotherapy in wart cases and MBL as regards its serum level and genotypes.

Conclusions

MBL play an important role in host defense against HPV infection

Keywords:

• Mannose Binding Lectin
• warts
• candida antigen

Disclosure statement

No potential conflict of interest was reported by the authors.

Figure 1. Multiple planter warts at right sole. (A) Before treatment. (B) After six settings of intralesional Candida antigen immunotherapy.